How Iwilfin Works Against Neuroblastoma
Iwilfin (eflornithine hydrochloride) treats high-risk neuroblastoma in patients aged 1 year and older after tumor cells no longer circulate in the blood and bone marrow following initial therapy like stem cell transplant, radiation, and chemotherapy. It reduces relapse risk by blocking an enzyme called ornithine decarboxylase (ODC), which limits polyamine production—molecules cancer cells need to grow and survive.[1][2]
What Is Neuroblastoma and Why Target It This Way?
Neuroblastoma is a rare cancer from immature nerve cells, often in children, that can spread to bone marrow and blood. Standard treatments aim for remission, but high-risk cases relapse in up to 50% of patients. Iwilfin fills a gap in maintenance therapy by sustaining remission without attacking tumors directly; instead, it starves residual microscopic disease of polyamines, slowing regrowth.[1][3]
How Patients Take Iwilfin and What Results Show
Patients take Iwilfin as an oral solution twice daily for two years. In the pivotal Phase 3 trial (INT0214), it cut 2-year event-free survival relapse risk by 37% versus observation alone (84% vs. 74%). Median follow-up reached 3 years with no new safety signals.[1][4]
Common Side Effects and Monitoring
Most side effects are mild: ear infections (26%), low white blood cell counts (24%), diarrhea (17%), and vomiting (16%). Hearing loss occurs in 2-5% of cases, so audiograms are checked every 3 months. No treatment deaths linked to Iwilfin.[1][2]
How Iwilfin Compares to Other Neuroblastoma Maintenance Options
Unlike chemotherapy or immunotherapy (e.g., dinutuximab), Iwilfin is non-cytotoxic and oral, avoiding infusions or severe toxicity. It's FDA-approved (December 2023) as the first oral maintenance drug for this use, often combined with prior dinutuximab. No direct head-to-head trials exist with alternatives like isotretinoin.[1][3]
When Can Generic or Biosimilar Versions Arrive?
Iwilfin has orphan drug exclusivity until December 2030 and pediatric exclusivity to June 2031. Patents listed on DrugPatentWatch include U.S. Patent 11,013,713 (expires 2039) covering the formulation. No Paragraph IV challenges filed yet.5
[1]: FDA Label for Iwilfin (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215500s000lbl.pdf)
[2]: Memorial Sloan Kettering Cancer Center summary (https://www.mskcc.org/cancer-care/patient-education/medications/pediatric/eflornithine)
[3]: New England Journal of Medicine (NEJM) trial publication (https://www.nejm.org/doi/full/10.1056/NEJMoa2109320)
[4]: COG Study INT0214 results (https://ascopubs.org/doi/10.1200/JCO.22.02171)